Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 20/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 20/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570572 | 0.82 | PDE3B (0.60) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL1570935 | 0.82 | PDE3B (0.60) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL7306463 | 0.82 | PDE3B (0.70) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Hydrochloric Acid SCHEMBL10605149 | 0.81 | PDE3B (0.58) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL1571161 | 0.80 | PDE3B (0.60) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL1571257 | 0.80 | PDE3B (0.75) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL7302448 | 0.79 | PDE3B (0.56) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL10602377 | 0.78 | PDE3B (0.55) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL11866311 | 0.76 | PDE3B (0.52) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| SCHEMBL1570768 | 0.75 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | GARVEY DAVID S (US) | 2004-05-06 | — | — | US | claimed |
| US-6472425-B1 | Methods for treating female sexual dysfunctions | NITROMED, INC. | 2002-10-29 | — | — | US | claimed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | claimed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | claimed |
| US-6197778-B1 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2001-03-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | PDE3B 2/4885PDE3A 1/4885P2RY12 514/4885 |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885P2RY12 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.